Evidence map›Paper›PMID 39633144›Full record

ArticleCerebellum (London, England)2024

Clinical and Laboratory Features Predict Phenoconversion from Sporadic Adult-onset Ataxia to Multiple System Atrophy.

Tina Liu, Monica Johnson, Negin Badihian, William S Harmsen, Jay Mandrekar, Lauren M Jackson, Eduardo E Benarroch, Paola Sandroni, Phillip A Low, Wolfgang Singer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tina LiuDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Monica JohnsonDepartment of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
Negin BadihianDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
William S HarmsenDepartment of Biostatistics, Mayo Clinic, Rochester, MN, USA.
Jay MandrekarDepartment of Biostatistics, Mayo Clinic, Rochester, MN, USA.
Lauren M JacksonDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Eduardo E BenarrochDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Paola SandroniDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Phillip A LowDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Wolfgang SingerDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Elizabeth A CoonDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Coon.elizabeth@mayo.edu.

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Synucleinopathies – Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic ApproachR01NS092625 · NINDS · MAYO CLINIC ROCHESTER · PI SINGER, WOLFGANG, VEMURI, PRASHANTHI · 2015 to 2025
$6.6M
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System AtrophyR01FD007290 · FDA · MAYO CLINIC ROCHESTER · PI SINGER, WOLFGANG · 2021 to 2024
$3.2M
Center for Clinical and Translational Science, Mayo Clinic UL1TR000135FDA HHS R01 FD007290FDA HHS R01 FD07290NIH HHS R01 NS92625NINDS NIH HHS R01 NS092625
6 · The paper itself

Abstract

To determine predicting factors and frequency of phenoconversion from sporadic adult-onset ataxia (SAOA) to multiple system atrophy (MSA). We performed a retrospective review of all patients referred for cerebellar ataxia from 1998 to 2018 at Mayo Clinic, Minnesota. We analyzed clinical features, autonomic testing, and imaging for predictors of later diagnosis of MSA. Among 169 patients with ataxia at presentation, 60 (35.5%) phenoconverted to MSA. Clinical features in MSA phenoconverters included: early autonomic symptoms, stridor, and dream enactment behavior. Imaging features in phenoconverters included pontine atrophy and hot cross bun sign. On autonomic testing, MSA phenoconverters had higher supine blood pressures with larger drops, higher median composite autonomic severity scores, and higher percentage anhidrosis than patients with SAOA. Our findings show that at least a third of patients with SAOA phenoconverted to MSA. Clinical features, autonomic testing, and imaging at presentation may be helpful to identify such patients.

Indexed as

Multiple System AtrophyAdultAgedAge of OnsetCerebellar AtaxiaFemaleHumansMaleMiddle AgedRetrospective StudiesAtaxiaCerebellumMultiple system atrophyOrthostatic hypotensionStridor

Identifiers

PMID39633144
PMCPMC13019531

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.